Article info
PDFClinical and epidemiological research
Extended report
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
- Correspondence to Professor A Kavanaugh, Center for Innovative Therapy, Division of Rheumatology, Allergy & Immunology, School of Medicine, University of California San Diego, 9500 Gilman Drive #0656, La Jolla, CA 92093, USA; akavanaugh{at}ucsd.edu
Citation
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
Publication history
- Received June 22, 2016
- Revised November 1, 2016
- Accepted November 5, 2016
- First published December 19, 2016.
Online issue publication
June 20, 2023
Article Versions
- Previous version (31 October 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/